13Mar

[Articles] The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson’s disease: a cross-sectional PET study

LRRK2 mutations are associated with significantly increased cholinergic activity in the brain in mutation carriers without Parkinson's disease compared with healthy controls and in LRRK2 mutation carriers with Parkinson's disease compared with individuals with idiopathic disease. Changes in cholinergic activity might represent early and sustained attempts to compensate for LRRK2-related dysfunction, or alteration of acetylcholinesterase in non-neuronal cells.

Ander nieuws

20May

[Comment] A new step towards targeting tau

Progressive supranuclear palsy is a rare neurodegenerative disease characterised by an axial parkins...

naar nieuwsitem

20May

[Review] CSF and blood biomarkers for Parkinson’s disease

In the management of Parkinson's disease, reliable diagnostic and prognostic biomarkers are urg...

naar nieuwsitem

22Apr

Parkinson’s disease patient: ‘I can walk… it’s really helped me’

Parkinson's disease patient Gail Jardine can walk more freely after having a spinal implant fit...

naar nieuwsitem